515 related articles for article (PubMed ID: 28025059)
1. MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis.
Wu H; Zhang T; Pan F; Steer CJ; Li Z; Chen X; Song G
J Hepatol; 2017 Apr; 66(4):816-824. PubMed ID: 28025059
[TBL] [Abstract][Full Text] [Related]
2. A negative feedback loop between microRNA-378 and Nrf1 promotes the development of hepatosteatosis in mice treated with a high fat diet.
Zhang T; Zhao X; Steer CJ; Yan G; Song G
Metabolism; 2018 Aug; 85():183-191. PubMed ID: 29625129
[TBL] [Abstract][Full Text] [Related]
3. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway.
Wu H; Ng R; Chen X; Steer CJ; Song G
Gut; 2016 Nov; 65(11):1850-1860. PubMed ID: 26282675
[TBL] [Abstract][Full Text] [Related]
5. Decrease of microRNA-122 causes hepatic insulin resistance by inducing protein tyrosine phosphatase 1B, which is reversed by licorice flavonoid.
Yang YM; Seo SY; Kim TH; Kim SG
Hepatology; 2012 Dec; 56(6):2209-20. PubMed ID: 22807119
[TBL] [Abstract][Full Text] [Related]
6. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
7. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
Liu X; Chen S; Zhang L
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1.
Zhang M; Sun W; Zhou M; Tang Y
Sci Rep; 2017 Nov; 7(1):14493. PubMed ID: 29101357
[TBL] [Abstract][Full Text] [Related]
9. Long Noncoding RNA lncSHGL Recruits hnRNPA1 to Suppress Hepatic Gluconeogenesis and Lipogenesis.
Wang J; Yang W; Chen Z; Chen J; Meng Y; Feng B; Sun L; Dou L; Li J; Cui Q; Yang J
Diabetes; 2018 Apr; 67(4):581-593. PubMed ID: 29382663
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
[TBL] [Abstract][Full Text] [Related]
11. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
12. NFE2 Induces miR-423-5p to Promote Gluconeogenesis and Hyperglycemia by Repressing the Hepatic FAM3A-ATP-Akt Pathway.
Yang W; Wang J; Chen Z; Chen J; Meng Y; Chen L; Chang Y; Geng B; Sun L; Dou L; Li J; Guan Y; Cui Q; Yang J
Diabetes; 2017 Jul; 66(7):1819-1832. PubMed ID: 28411267
[TBL] [Abstract][Full Text] [Related]
13. A novel role of CRTC2 in promoting nonalcoholic fatty liver disease.
Han HS; Kim SG; Kim YS; Jang SH; Kwon Y; Choi D; Huh T; Moon E; Ahn E; Seong JK; Kweon HS; Hwang GS; Lee DH; Cho KW; Koo SH
Mol Metab; 2022 Jan; 55():101402. PubMed ID: 34838715
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.
Ng R; Wu H; Xiao H; Chen X; Willenbring H; Steer CJ; Song G
Hepatology; 2014 Aug; 60(2):554-64. PubMed ID: 24677249
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway.
Zhang T; Hu J; Wang X; Zhao X; Li Z; Niu J; Steer CJ; Zheng G; Song G
J Hepatol; 2019 Jan; 70(1):87-96. PubMed ID: 30218679
[TBL] [Abstract][Full Text] [Related]
16. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
Long JK; Dai W; Zheng YW; Zhao SP
Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-185 regulates expression of lipid metabolism genes and improves insulin sensitivity in mice with non-alcoholic fatty liver disease.
Wang XC; Zhan XR; Li XY; Yu JJ; Liu XM
World J Gastroenterol; 2014 Dec; 20(47):17914-23. PubMed ID: 25548489
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-103 represses hepatic de novo lipogenesis and alleviates NAFLD via targeting FASN and SCD1.
Zhang M; Tang Y; Tang E; Lu W
Biochem Biophys Res Commun; 2020 Apr; 524(3):716-722. PubMed ID: 32035613
[TBL] [Abstract][Full Text] [Related]
19. miR-32-5p induces hepatic steatosis and hyperlipidemia by triggering de novo lipogenesis.
Wang YD; Wu LL; Mai YN; Wang K; Tang Y; Wang QY; Li JY; Jiang LY; Liao ZZ; Hu C; Wang YY; Liu JJ; Liu JH; Xiao XH
Metabolism; 2023 Sep; 146():155660. PubMed ID: 37451670
[TBL] [Abstract][Full Text] [Related]
20. Chokeberry attenuates the expression of genes related to de novo lipogenesis in the hepatocytes of mice with nonalcoholic fatty liver disease.
Park H; Liu Y; Kim HS; Shin JH
Nutr Res; 2016 Jan; 36(1):57-64. PubMed ID: 26773781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
